Koehler A, Eyssel J, Nieder TO. Genders and Individual Treatment Progress in (Non-). Binary Trans Individuals. J. Sex. Med. 2018;15(1):102–113. [PubMed: 29229223]
Wiepjes CM, Nota NM, Blok CJM, De, Klaver M, Vries ALC, De, Wensing-kruger SA, Jongh RT, De, Bouman M, Steensma TD, Cohen-kettenis P, Gooren LJG, Kreukels BPC, den Heijer M. The Amsterdam Cohort of Gender Dysphoria Study (1972 e 2015) : Trends in Prevalence, Treatment, and Regrets. J. Sex. Med. 2018;15:582–590. [PubMed: 29463477]
Polderman TJC, Kreukels BPC, Irwig MS, Beach L, Chan YM. The Biological Contributions to Gender Identity and Gender Diversity : Bringing Data to the Table. Behav. Genet. 2018;48(2):95–108. [PubMed: 29460079]
Swaab DF. Sexual differentiation of the brain and behavior. Best Pract. Res. Clin. Endocrinol. Metab. 2007;21(3):431–444. [PubMed: 17875490]
Coleman E, Bockting W, Botzer M, Cohen-Kettenis PT, DeCuypere G, Feldman J, Fraser L, Green J, Knudson G, Meyer WJ, Monstrey S, Adler RK, Brown GR, Zucker K. Standards of Care, for the Health of Transsexual, Transgender, and Gender Nonconforming People. Int. J. Tansgenderism. 2012;13:165–232.
Van De Grift TC, Elaut E, Cerwenka SC, Cohen-Kettenis PT, De Cuypere G, Richter-Appelt H, Kreukels BPC. Effects of Medical Interventions on Gender Dysphoria and Body Image: A Follow-Up Study. Psychosom. Med. 2017;79:815–823. [PMC free article: PMC5580378] [PubMed: 28319558]
Bradford J, Reisner SL, Honnold JA, Xavier J. Experiences of Transgender-Related Discrimination and Implications for Health : Results From the Virginia Transgender Health Initiative Study. Res. Pract. 2013;103(10):1820–1829. [PMC free article: PMC3780721] [PubMed: 23153142]
Budge SL, Adelson JL, Howard KAS. Anxiety and Depression in Transgender Individuals: The Roles of Transition Status, Loss, Social Support, and Coping. J. Consult. Clin. Psychol. 2013;81(3):545–557. [PubMed: 23398495]
Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017;5:291–300. [PMC free article: PMC5366074] [PubMed: 27916515]
Hembree WC, Cohen-kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V. T’Sjoen GG. Endocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2017;102(11):1–35. [PubMed: 28945902]
Prior JC. Progesterone is important for transgender women’s therapy-applying evidence for the benefits of progesterone in ciswomen. J. Clin. Endocrinol. Metab. 2019;104:1181–1186. [PubMed: 30608551]
Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex. Med. Rev. 2018;6:77–85. [PMC free article: PMC5690890] [PubMed: 28526632]
De Blok CJM, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, Schreiner T. T’Sjoen G, Den Heijer M. Breast development in transwomen after 1 year of cross-sex hormone therapy: Results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 2018;103:532–538. [PubMed: 29165635]
Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclaire C, Barrett J. Predictive Markers for Mammoplasty and a Comparison of Side Effect Profiles in Transwomen Taking Various Hormonal Regimens. J Clin Endocrinol Metab. 2012;97:4422–4428. [PubMed: 23055547]
Callewaert F, Sinnesael M, Gielen E, Boonen S, Vanderschueren D. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J. Endocrinol. 2010;207:127–34. [PubMed: 20807726]
Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C, Nippoldt TB, Prokop LJ, Murad MH. Effect of sex steroids on the bone health of transgender individuals: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2017;102:3904–3913. [PubMed: 28945851]
Van Caenegem E, Taes Y, Wierckx K, Vandewalle S, Toye K, Kaufman JM, Schreiner T, Haraldsen I. T’Sjoen G. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013;54:92–97. [PubMed: 23369987]
Wiepjes CM, de Jongh RT, de Blok CJ, Vlot MC, Lips P, Twisk JW, den Heijer M. Bone Safety During the First Ten Years of Gender-Affirming Hormonal Treatment in Transwomen and Transmen. J. Bone Miner. Res. 2018. doi[Epub ahead of print] [PMC free article: PMC7816092] [PubMed: 30537188] [CrossRef]
Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, Toye K, Kaufman JM. T’Sjoen GG. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008;43:1016–1021. [PubMed: 18835591]
Ruetsche AG, Kneubuehl R, Birkhaeuser MH, Lippuner K. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: A cross-sectional study. Osteoporos. Int. 2005;16:791–798. [PubMed: 15502960]
Sosa M, Jódar E, Arbelo E, Domínguez C, Saavedra P, Torres A, Salido E, de Tejada MJG, Hernández D. Bone Mass, Bone Turnover, Vitamin D, and Estrogen Receptor Gene Polymorphisms in Male to Female Transsexuals. J. Clin. Densitom. 2003;6:297–304. [PubMed: 14515001]
Kuchuk NO, Van Schoor NM, Pluijm SMF, Smit JH, De Ronde W, Lips P. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin. Endocrinol. (Oxf). 2007;67:295–303. [PubMed: 17555504]
Fabbre VD. Gender Transitions in Later Life: The Significance of Time in Queer Aging. J. Gerontol. Soc. Work. 2014;57:161–175. [PMC free article: PMC4051396] [PubMed: 24798691]
Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van De Peer F, Toye K, Kaufman JM. T’Sjoen G. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J. Clin. Endocrinol. Metab. 2012;97:2503–2511. [PubMed: 22564669]
Haraldsen IR, Haug E, Falch J, Egeland T, Opjordsmoen S. Cross-sex pattern of bone mineral density in early onset gender identity disorder. Horm. Behav. 2007;52:334–343. [PubMed: 17604029]
Petrea RE, Beiser AS, Seshadri S, Kelly-hayes M, Kase CS, Wolf PA. Gender Differences in Stroke Incidence and Poststroke Disability in the Framingham Heart Study. Stroke. 2009;40:1032–1037. [PMC free article: PMC2676725] [PubMed: 19211484]
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler IER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart Disease and Stroke Statistics - 2014 Update: A report from the American Heart Association. Circulation. 2014;129:e28–e292. [PMC free article: PMC5408159] [PubMed: 24352519]
Appelros P, Stegmayr B, Terént A. Sex Differences in Stroke Epidemiology. Stroke. 2009;40:1082–1090. [PubMed: 19211488]
Albrektsen G, Heuch I, Løchen ML, Thelle DS, Wilsgaard T, Njølstad I, Bønaa KH. Lifelong gender gap in risk of incident myocardial infarction: The Tromsø study. JAMA Intern. Med. 2016;176:1673–1679. [PubMed: 27617629]
Bleker SM, Coppens M, Middeldorp S. Blood Reviews Sex, thrombosis and inherited thrombophilia. Blood Rev. 2014;28(3):123–133. [PubMed: 24768093]
Roach REJ, Lijfering WM, Rosendaal FR, Cannegieter SC, le Cessie S. Sex Difference in Risk of Second but Not of First Venous Thrombosis. Circulation. 2014;129:51–56. [PubMed: 24146250]
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-termhormone therapy for perimenopausal and postmenopausalwomen. Cochrane Database Syst Rev. 2017;1:CD004143. pub5
Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. LANCET Diabetes Endocrinol. 2016;8587(16):943–956. [PubMed: 27669646]
Martinez C, Suissa S, Rietbrock S, Katholing A, Freedman B, Cohen AT, Handelsman DJ. Testosterone treatment and risk of venous thromboembolism : population based case-control study. BMJ 2016;355(June):i.5968. [PMC free article: PMC5130924] [PubMed: 27903495]
Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men : a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:1–12. [PMC free article: PMC3648456] [PubMed: 23597181]
Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989;38:869–873. [PubMed: 2528051]
van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin. Endocrinol. (Oxf). 1997;47:337–342. [PubMed: 9373456]
Nota NM, Wiepjes CM, de Blok CJ, Gooren LJ, Kreukels BP, den Heijer M. The occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study. Circulation. 2019. [PubMed: 30776252] [CrossRef]
Getahun D, Nash R, Flanders WD, Baird TC, Becerra-culqui TA, Cromwell L, Hunkeler E, Lash TL, Millman A, Quinn VP, Robinson B, Roblin D, Silverberg MJ, Safer J, Slovis J, Tangpricha V, Goodman M. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons. Ann. Intern. Med. 2018;169:205–213. [PMC free article: PMC6636681] [PubMed: 29987313]
Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, Kaufman JM. T’Sjoen G. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case – control study. Eur. J. Endocrinol. 2013;169:471–478. [PubMed: 23904280]
Selier N, Cannegieter S, Venemans-Jellema A, den Heijer M. Moderate cross-sex hormone-induced prothrombotic changes of hemostatic variables in transgender subjects. In: Endocrine Abstracts (2016) 41 EP207 | DOI: 10.1530/endoabs.41.EP207. [CrossRef]
Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ. 2008;336:1227–1231. [PMC free article: PMC2405857] [PubMed: 18495631]
Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ. 2010;341:83. [PubMed: 20525678]
Dragoman M V., Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int. J. Gynecol. Obstet. 2018;141:287–294. [PMC free article: PMC5969307] [PubMed: 29388678]
Asscheman H, Giltay EJ, Megens JAJ, Ronde WP, De, Trotsenburg MAA, Van A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol. 2011;164:635–642. [PubMed: 21266549]
Van Velzen DM, Paldino A, Klaver M, Nota NM, Defreyne J, Kees Hovingh G, Thijs A, Simsek S, Sjoen GT, Den Heijer M. Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J. Clin. Endocrinol. Metab. 2019;104:1937–1947. [PubMed: 30602016]
Maraka S, Singh Ospina N, Rodriguez-gutierrez R, Davidge-pitts CJ, Nippoldt TB, Prokop LJ, Murad MH. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 2017;102:3914–3923. [PubMed: 28945852]
Collaborators G. 2015 M and C of D. Global, regional, and national life expectancy, all-cause mortality, and cause-specifi c mortality for 249 causes of death, 1980 – 2015 : a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544. [PMC free article: PMC5388903] [PubMed: 27733281]
Blankenstein MA, Verheijen M, Jacobs JM, Donker TH, Duijnhoven MWF, Van, Thijssen JHH. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids. 2000;65:795–800. [PubMed: 11108890]
Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Futur. Oncol. 2010;6:1771–1779. [PMC free article: PMC3077966] [PubMed: 21142662]
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2017. DOI. [PMC free article: PMC6465148] [PubMed: 28093732] [CrossRef]
Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78:782–785. [PubMed: 23624028]
Karlsson CT, Malmer B, Wiklund F, Grönberg H. Breast Cancer as a Second Primary in Patients With Prostate Cancer — Estrogen Treatment or Association With Family History of Cancer ? J. Urol. 2006;176(August):538–543. [PubMed: 16813884]
Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol. 2008;159(3):197–202. [PubMed: 18567667]
Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M. Cancer in transgender people: Evidence and methodological considerations. Epidemiol. Rev. 2017;39:93–107. [PMC free article: PMC5868281] [PubMed: 28486701]
Maglione K, Margolies L, Jaffer S, Szabo J, Schmidt H, Weltz C, Sonnenblick E. Breast cancer in male-to-female transsexuals: use of breast imaging for detection. Am. J. Roentgenol. 2014;47:W735–W740. [PubMed: 25415740]
Gooren LJ, van Trotsenburg MAA, Giltay EJ, van Diest PJ. Breast Cancer Development in Transsexual Subjects Receiving Cross-Sex Hormone Treatment. J. Sex. Med. 2013;10:3129–3134. [PubMed: 24010586]
Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res. Treat. 2015;149:191–198. [PubMed: 25428790]
de Blok CJ, Wiepjes CM, Nota NM, van Engelen K, Adank MA, Dreijerink KM, Barbé E, Konings IR, den Heijer M. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019. BMJ. 2019;365:l1652. [PMC free article: PMC6515308] [PubMed: 31088823]
Chlebowski RT, Aragaki AK, Anderson GL. Menopausal hormone therapy influence on breast cancer outcomes in the women’s health initiative. JNCCN J. Natl. Compr. Cancer Netw. 2015;13:917–924. [PubMed: 26150583]
Nelles JL, Hu WY, Prins GS. Estrogen action and prostate cancer. Expert Rev. Endocrinol. Metab. 2011;6:437–451. [PMC free article: PMC3134227] [PubMed: 21765856]
Deebel NA, Morin JP, Autorino R, Vince R, Grob B, Hampton LJ. Prostate Cancer in Transgender Women: Incidence, Etiopathogenesis, and Management Challenges. Urology. 2017;110:166–171. [PubMed: 28882782]
Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G. T’Sjoen G. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J. Sex. Med. 2012;9(10):2641–51. [PubMed: 22906135]
Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014;46:1156–1160. [PubMed: 24329588]
Defreyne J, Nota N, Pereira C, Schreiner T, Fisher AD, den Heijer M TG. Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment. LGBT Heal. 2017;4(5):328–336. [PubMed: 28880825]
Nota N, Dekker MJHJ, Wiepjes MKCM, Van Trotsenburg M, Heijboer MC, Den Heijer M. Prolactin levels during short- and long- term cross- sex hormone treatment : an observational study in transgender persons. Andrologia 2017;49:Epub 2016 Aug 25. [PubMed: 27561756]
Nota NM, Wiepjes CM, De Blok CJM, Gooren LJG, Peerdeman SM, Kreukels BPC, Den Heijer M. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018;141:2047–2054. [PubMed: 29688280]
Ter Wengel P V, Martin E, Gooren L, den Heijer M, Peerdeman SM. Meningiomas in three male-to-female transgender subjects using oestrogens / progestogens and review of the literature. Andrologia. 2016;48(48):1130–37. [PubMed: 26888610]
Hutchison LM, Boscoe FP, Feingold BJ. Cancers disproportionately affecting the New York state transgender population, 1979-2016. Am. J. Public Health. 2018;108:1260–1262. [PMC free article: PMC6085041] [PubMed: 30024801]
Bollo J, Balla A, Rodriguez Luppi C, Martinez C, Quaresima S, Targarona EM. HPV-related squamous cell carcinoma in a neovagin* after male-to-female gender confirmation surgery. Int. J. STD AIDS. 2018;29:306–308. [PubMed: 28853678]
Fernandes HM, Manolitsas TP, Jobling TW. Carcinoma of the neovagin* after male-to-female reassignment. J. Low. Genit. Tract Dis. 2014;18:E43–5. [PubMed: 23994948]
Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: Two cases with a review of physiology and management. Clin. Breast Cancer. 2011;11:417–419. [PubMed: 21831723]
Stone JP, Hartley RL, Temple-Oberle C. Breast cancer in transgender patients: A systematic review. Part 2: Female to Male. Eur. J. Surg. Oncol. 2018;44:1463–1468. [PubMed: 30037639]
Nikolic D V., Djordjevic ML, Granic M, Nikolic AT, Stanimirovic V V., Zdravkovic D, Jelic S. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J. Surg. Oncol. 2012;10:280. [PMC free article: PMC3554459] [PubMed: 23273269]
Burcombe RJ, Makris A, Pittam M, Finer N. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast. 2003;12:290–293. [PubMed: 14659317]
Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome : a review analysis. Hippokratia. 2009;13:90–92. [PMC free article: PMC2683463] [PubMed: 19561777]
Urban RR, Teng NNH, Kapp DS. Gynecologic malignancies in female-to-male transgender patients: The need of original gender surveillance. Am. J. Obstet. Gynecol. 2011;204:e9–e12. [PubMed: 21354550]
Rinaldi S, Plummer M, Biessy C, Castellsagué X, Overvad K, Kjær SK, Tjønneland A, Clavel-Chapelon F, Chabbert-Buffet N, Mesrine S, Lukanova A, Kaaks R, Weikert C, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita B, Van Kranen HJ, Peeters PHM, Bakken K, Lund E, Gram IT, Rodríguez L, Xavier Bosch F, Sańchez MJ, Dorronsoro M, Navarro C, Gurrea AB, Kjellberg L, Dillner J, Manjer J, Butt S, Khaw KT, Wareham N, Allen NE, Travis R, Romieu I, Ferrari P, Riboli E, Franceschi S. Endogenous sex steroids and risk of cervical carcinoma: Results from the EPIC study. Cancer Epidemiol. Biomarkers Prev. 2011;20:2532–2540. [PubMed: 21994406]
Driák D, Samudovský M. Could a man be affected with carcinoma of cervix?--The first case of cervical carcinoma in trans-sexual person (FtM)--case report. Acta medica (Hradec Kral. 2005;48:53–5. [PubMed: 16080386]
Bartlett JMS, Langdon SP, Simpson BJB, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams ARW, Lessells AM, Macleod KG, Smyth JF, Miller WR. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer. 1996;73:301–306. [PMC free article: PMC2074444] [PubMed: 8562334]
Hage JJ, Dekker JJML, Karim RB, Verheijen RHM, Bloemena E. Ovarian cancer in female-to-male transsexuals: Report of two cases. Gynecol. Oncol. 2000;76:413–415. [PubMed: 10684720]
Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol. Obstet. Invest. 2006;62:226–228. [PubMed: 16804313]
Colebunders B, Brondeel S, D’Arpa S, Hoebeke P, Monstrey S. An Update on the Surgical Treatment for Transgender Patients. Sex. Med. Rev. 2017;5:103–109. [PubMed: 27623991]
Morrison SD, Vyas KS, Motakef S, Gast KM, Chung MT, Rashidi V, Satterwhite T, Kuzon W, Cederna PS. Facial Feminization: Systematic Review of the Literature. Plast. Reconstr. Surg. 2016;137:1759–1770. [PubMed: 27219232]
Cohen MB, Insalaco LF, Tonn CR, Spiegel JH. Patient Satisfaction after Aesthetic Chondrolaryngoplasty. Plast. Reconstr. Surg. - Glob. Open. 2018;6:e1877. [PMC free article: PMC6250475] [PubMed: 30534483]
Louie M, Moulder JK. Hysterectomy for the Transgender Man. Curr. Obstet. Gynecol. Rep. 2017;6:126–132.
Groenman F, Nikkels C, Huirne J, van Trotsenburg M, Trum H. Robot-assisted laparoscopic colpectomy in female-to-male transgender patients; technique and outcomes of a prospective cohort study. Surg. Endosc. 2017;31:3363–3369. [PMC free article: PMC5501901] [PubMed: 27844235]
Djordjevic ML. Novel surgical techniques in female to male gender confirming surgery. Transl. Androl. Urol. 2018;7:628–638. [PMC free article: PMC6127556] [PubMed: 30211052]
Tornello SL, Bos H. Parenting Intentions Among Transgender Individuals. LGBT Heal. 2017;4:115–120. [PubMed: 28212056]
Mattawanon N, Spencer JB, Schirmer DA, Tangpricha V. Fertility preservation options in transgender people: A review. Rev. Endocr. Metab. Disord. 2018;19:231–242. [PubMed: 30219984]
De Sutter P, Kira K, Verschoor A, Hotimsky A. The desire to have children and the preservation of fertility in transsexual women: A survey. Int. J. Transgenderism. 2002;6:1–12.
Wierckx K, Van Caenegem E, Pennings G, Elaut E, Dedecker D, Van De Peer F, Weyers S, De Sutter P. T’Sjoen G. Reproductive wish in transsexual men. Hum. Reprod. 2012;27:483–487. [PubMed: 22128292]
Walton-Betancourth S, Monti E, Adu-Gyamfi K, Roberts A, Clarkson K, Ward S, Butler G. Fertility preservation for transgender adolescents: The parent’s view. Endocr. Abstr. 58 P030 | DOI 10.1530/endoabs.58.P030. doi: 10.1530/endoabs.58.p030. [CrossRef] [CrossRef]
Bouman WP, Claes L, Marshall E, Pinner GT, Longworth J, Maddox V, Witcomb G, Jimenez-Murcia S, Fernandez-Aranda F, Arcelus J. Sociodemographic Variables, Clinical Features, and the Role of Preassessment Cross-Sex Hormones in Older Trans People. J. Sex. Med. 2016;13:711–719. [PubMed: 26897462]
Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM. Testosterone replacement therapy among elderly males: The Testim Registry in the US (TRiUS). Clin. Interv. Aging. 2012;7:321–330. [PMC free article: PMC3430096] [PubMed: 22956867]
Klaver M, De Blok CJM, Wiepjes CM, Nota NM, Dekker MJHJ, De Mutsert R, Schreiner T, Fisher AD. T’Sjoen G, Den Heijer M. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: Results from a multicenter prospective study. Eur. J. Endocrinol. 2018;178:163–171. [PubMed: 29183889]
Streed CG, Harfouch O, Marvel F, Blumenthal RS, Martin SS, Mukherjee M. Cardiovascular disease among transgender adults receiving hormone therapy: A narrative review. Ann. Intern. Med. 2017;167:256–267. [PubMed: 28738421]
Cohen-Kettenis PT, Pfäfflin F. The DSM diagnostic criteria for gender identity disorder in adolescents and adults. Arch. Sex. Behav. 2010;39:499–513. [PubMed: 19838784]
Rotondi NK, Bauer GR, Scanlon K, Kaay M, Travers R, Travers A. Nonprescribed hormone use and self-performed surgeries: “do-it-yourself” transitions in transgender communities in Ontario, Canada. Am. J. Public Health. 2013;103:1830–1836. [PMC free article: PMC3780733] [PubMed: 23948009]
Gooren LJ, Sungkaew T, Giltay EJ. Exploration of functional health, mental well-being and cross-sex hormone use in a sample of Thai male-to-female transgendered persons (kathoeys). Asian J. Androl. 2013;15:280–285. [PMC free article: PMC3739151] [PubMed: 23353716]
Becerra-Fernández A, de Luis Roman DA, Piedrola Maroto G. Morbidity in transsexual patients with cross-gender hormone self-treatment. Med. Clin. (Barc). 1999;113:484–487. [PubMed: 10604171]
Toorians AWFT, Thomassen MCLGD, Zweegman S, Magdeleyns EJP, Tans G, Gooren LJG, Rosing J. Venous Thrombosis and Changes of Hemostatic Variables during Cross-Sex Hormone Treatment in Transsexual People. J. Clin. Endocrinol. Metab. 2003;88:5723–5729. [PubMed: 14671159]
Mepham N, Bouman WP, Arcelus J. People with Gender Dysphoria Who Self-Prescribe Cross-Sex Hormones: Prevalence, Sources, and Side Effects Knowledge. J Sex Med. 2014;11:2995–3001. [PubMed: 25213018]
